Trial Profile

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Mar 2026 According to a Clarity pharmaceuticals media release, results from the Co-PSMA trial published in European Urology, the official journal of the European Association of Urology (EAU) Congress 2026.
31 Mar 2026 Results presented in the Clarity pharmaceuticals Media Release.
17 Mar 2026 According to a Clarity pharmaceuticals media release, data from the trial is intended to be submitted to the United States (US) Food and Drug Administration (FDA) for a market authorisation of 64Cu-SAR-bisPSMA in patients with BCR of prostate cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com